Synthetic Biologics, Enterome Bioscience to collaborate on C. diff study
Enterome will conduct a microbiome study to better understand the harmful effects of beta-lactam antibiotics on the gastrointestinal microflora of human patients. The research, which will use 100 patients, is aimed at providing insight to Synthetic Biologics as it conducts clinical trials of its SYN-004 treatment against C. diff infection.
"We are pleased to establish this collaboration with Enterome, a pioneer in the development of biomarkers and therapies for diseases of the gut microbiome," Jeffrey Riley, the CEO of Synthetic Biologics, said. "Findings from this study should support our C. diff therapeutic program, which focuses on protecting and maintaining the balance of bacterial microflora in the gut, while also establishing our presence in Europe."
The Enterome study, scheduled to be finished by the second half of this year, will seek to establish a "fingerprint" of the damage caused by beta-lactam antibiotics, creating bacterial biomarkers that can be used for further tests.
SYN-004 is the first therapy designed to neutralize IV antibiotics in the gut, which is usually when C. diff infections occur. Phase 1a and 1b clinical trials of the treatment are scheduled to begin later this year.